BRIGHAM INC

Their core work

Brigham and Women's Hospital is a major Harvard-affiliated research hospital in Boston, contributing deep biomedical expertise to EU-funded projects primarily as a third-party host for visiting researchers under Marie Skłodowska-Curie fellowships. Their contributions span cancer mechanics, neuroscience, cardiovascular biology, rare diseases, and organ-on-a-chip technology. They serve as a world-class laboratory environment where European fellows access advanced imaging, electrophysiology, and nanotechnology platforms unavailable at their home institutions.

What they specialise in

How they've shifted over time

Early projects (2016-2019) centered on disease-specific research — cancer tissue mechanics (FORCE), autoimmune pathways in multiple sclerosis (DANTE), and rare disease clinical trials (STOPFOP). From 2021 onward, the focus shifted markedly toward technology-enabled biology: nanoelectrode-based electrophysiology (DynChan), organ-on-a-chip platforms (BrainChip4MED), and computational neuroscience (neuronsXnets). This evolution reflects a move from studying disease mechanisms toward building advanced experimental platforms that combine nanotechnology, biosensors, and in-vitro models.

Brigham is increasingly positioned at the intersection of nanotechnology and in-vitro disease modeling, making them a strong partner for projects needing organ-on-chip, biosensor, or nanoelectrode capabilities applied to biomedical questions.

How they like to work

Brigham operates almost exclusively as a third-party or minor participant — 7 of 9 projects list them as a partner, and they have never coordinated an H2020 project. This is typical for a US institution in EU framework programmes: they host European fellows and provide lab access rather than leading consortia. With 40 unique partners across 15 countries, they are a highly networked host institution that attracts researchers from diverse European groups.

Remarkably broad network for a non-EU institution: 40 unique consortium partners spread across 15 countries, built through hosting MSCA fellows from varied European research groups. Their connections span universities and research centers across the EU, making them a transatlantic bridge for biomedical collaboration.

What sets them apart

As a Harvard-affiliated US hospital participating in EU programmes, Brigham offers something few European partners can: access to one of the world's leading clinical research environments with integrated basic science labs. Their value lies not in EU project management but in providing fellows with world-class facilities in imaging, nanotechnology, and translational medicine. For consortium builders, adding Brigham signals scientific credibility and gives researchers access to patient cohorts and infrastructure difficult to replicate in Europe.

Highlights from their portfolio

• FORCE
  Largest funded project (EUR 49,375) combining MR-elastography with cancer biomechanics — a technically demanding imaging approach to understanding metastatic potential.
• BrainChip4MED
  Represents their newest direction: brain-on-a-chip platforms integrating biosensors and nanoformulations for screening treatments against neurodegenerative diseases.
• STOPFOP
  A rare disease clinical trial (fibrodysplasia ossificans progressiva) — one of very few therapeutic intervention studies in the portfolio, showing clinical trial capability.